U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB


(MARK ONE)

[X]  QUARTERLY  REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES  EXCHANGE ACT
     OF 1934 FOR THE QUARTERLY PERIOD ENDED FEBRUARY 29, 2000

[ ]  TRANSITION  REPORT UNDER SECTION 13 OR 15(d) OF THE  SECURITIES  EXCHANGE
     ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____________ TO _____________


COMMISSION FILE NUMBER:


                       L.O.M. MEDICAL INTERNATIONAL, INC.
        (Exact name of small business issuer as specified in its charter)

DELAWARE                                                             98-0178784
(State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer
incorporation or organization)  Classification Code Number)  Identification No.)

580-885 Dunsmuir Street, Vancouver, British Columbia, Canada             V6C 1N8
(Address of principal executive offices)                              (Zip Code)

                                 (604) 602-9400
                (Issuer's Telephone Number, including Area Code)



                              Thomas E. Stepp, Jr.
                              Stepp & Beauchamp LLP
                           1301 Dove Street, Suite 460
                         Newport Beach, California 92660
                             Telephone: 949.660.9700
                             Facsimile: 949.660.9010
            (Name, Address and Telephone Number of Agent for Service)


                APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check  whether  the issuer  (1) has filed all  reports  required  to be filed by
Section 13 or 15(d) of the  Exchange  Act during the past 12 months (or for such
shorter period that the  registrant was required to file such reports),  and (2)
has been subject to such filing  requirements  for the past 90 days. [X] Yes [ ]
No

                      APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of common
equity,  as of the latest  practical  date. As of February 29, 2000,  there were
5,610,099  shares of the  issuer's  $.001  par value  common  stock  issued  and
outstanding.


<PAGE>


                         PART I - FINANCIAL INFORMATION

Item 1.  Financial Statements

L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Balance Sheet
$ United States

February 29, 2000 and May 31, 1999
<TABLE>
<CAPTION>
----------------------------------------------------------------------------------
                                                               2000           1999

----------------------------------------------------------------------------------

Assets

<S>                                                     <C>            <C>
Current assets
     Cash                                               $   417,951    $   346,646
     Accounts receivable                                     29,337         26,442
     Prepaid expenses                                         1,467          3,453
----------------------------------------------------------------------------------
                                                            448,755        376,541

Product rights and patent costs (note 3)                     13,546         16,740

Capital assets (note 4)                                      41,009         49,869

----------------------------------------------------------------------------------
                                                        $   503,310    $   443,150
----------------------------------------------------------------------------------

Liabilities and Stockholders' Equity

Current liabilities
     Accounts payable and accrued liabilities           $    19,363    $    36,404

Redeemable preferred shares (note 5)                        301,727        301,727

Minority interest                                            (5,536)        (5,536)

Stockholders' equity
     Capital stock (note 6)                                   5,687          5,538
     Additional paid in capital                           1,640,321      1,233,721
     Deficit accumulated during the development stage    (1,481,648)    (1,152,030)
     Accumulated other comprehensive income                  23,396         23,326
----------------------------------------------------------------------------------
                                                            187,756        110,555

----------------------------------------------------------------------------------
                                                        $   503,310    $   443,150
----------------------------------------------------------------------------------
</TABLE>

See accompanying notes to financial statements

On behalf of the Board:

/s/ John Klippenstein
---------------------  Director

/s/ Pat [ILLEGIBLE]    Director
---------------------


                                        2
<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statement of Loss
$ United States

For the nine months ended February 29, 2000 and 1999
<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------------------------
                                                        From Inception
                                                      (March 17, 1997)               2000                      1999
                                                  to February 29, 2000
-------------------------------------------------------------------------------------------------------------------


<S>                                                     <C>                     <C>                     <C>
Expenses
     Advertising                                        $     9,663             $     1,438             $     3,547
     Amortization                                            34,051                  12,520                  13,246
     Automotive                                              40,260                  13,749                  11,899
     Consulting fees                                         60,859                  39,970                  15,667
     Design plans                                            10,911                      --                      --
     Director's fees                                         19,394                   3,970                   5,178
     Foreign exchange (gain) loss                            (6,199)                 (3,737)                  4,640
     Insurance                                                3,620                   1,639                     282
     Interest and bank charges                                5,772                   3,801                     776
     Legal and accounting                                   139,680                  57,701                  31,931
     Licenses, fees and dues                                  4,341                   3,476                     431
     Management fees                                        260,242                  45,729                  52,991
     Office and administration                              117,884                  26,668                  47,813
     Product development                                      1,582                      --                      --
     Promotion and entertainment                             12,161                   2,009                   3,199
     Rent                                                    91,302                  27,013                  25,313
     Repairs and maintenance                                  2,150                      --                     133
     Salaries                                                78,624                  78,624                      --
     Telephone and utilities                                 31,820                   8,609                  10,280
     Travel                                                  30,062                  15,109                   3,594
     Video production                                        21,343                   3,855                   7,436
     Write down of inventory                                 55,734                      --                      --
     Write down of product rights and
       patent costs                                         374,128                      --                      --
-------------------------------------------------------------------------------------------------------------------
                                                          1,399,384                 342,143                 238,356
-------------------------------------------------------------------------------------------------------------------
Loss from operations                                     (1,399,384)               (342,143)               (238,356)

Other income
     Interest income                                         50,472                  12,525                  16,211

-------------------------------------------------------------------------------------------------------------------
Net loss                                                $(1,348,912)            $  (329,618)            $  (222,145)
-------------------------------------------------------------------------------------------------------------------


Loss per share                                                                  $     (0.06)            $     (0.04)

Weighted average shares used                                                      5,550,663               5,512,383
-------------------------------------------------------------------------------------------------------------------
</TABLE>

See accompanying notes to financial statements


                                       3
<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statement of Loss
$ United States

For the three months ended February 29, 2000 and 1999
<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------------
                                                                2000                          1999
--------------------------------------------------------------------------------------------------


<S>                                                      <C>                           <C>
Expenses
     Advertising                                         $     1,433                   $     1,182
     Amortization                                              4,273                         4,415
     Automotive                                                5,562                         3,966
     Consulting fees                                          18,989                         5,222
     Director's fees                                           2,253                         1,726
     Foreign exchange (gain) loss                             (2,016)                        1,546
     Insurance                                                 1,639                            94
     Interest and bank charges                                 1,512                           259
     Legal and accounting                                     29,370                        10,643
     Licenses, fees and dues                                   3,291                           143
     Management fees                                             481                        17,664
     Office and administration                                 6,100                        15,938
     Promotion and entertainment                                 527                         1,066
     Rent                                                      9,296                         8,437
     Repairs and maintenance                                      --                            44
     Salaries                                                 47,034                            --
     Telephone and utilities                                   2,297                         3,427
     Travel                                                    4,859                         1,198
     Video production                                            926                         2,478
--------------------------------------------------------------------------------------------------
                                                             137,826                        79,448
--------------------------------------------------------------------------------------------------
Loss from operations                                        (137,826)                      (79,448)

Other income
     Interest income                                           6,037                         5,405

--------------------------------------------------------------------------------------------------
Net loss                                                 $  (131,789)                  $   (74,043)
--------------------------------------------------------------------------------------------------


Loss per share                                           $     (0.02)                  $     (0.01)

Weighted average shares used                               5,610,099                     5,519,547
--------------------------------------------------------------------------------------------------
</TABLE>

See accompanying notes to financial statements


                                       4
<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statement of Cash Flows
$ United States

For the nine months ended February 29, 2000 and 1999

<TABLE>
<CAPTION>
----------------------------------------------------------------------------------------------------------------
                                                        From inception
                                                      (March 17, 1997)               2000                 1999
                                                  to February 29, 2000
----------------------------------------------------------------------------------------------------------------

<S>                                                      <C>                   <C>                   <C>
Operating activities
   Net loss                                              $(1,348,912)          $  (329,618)          $  (222,145)

   Items not involving cash
     Amortization                                             34,051                12,520                13,246
     Write down of inventory                                  55,734                    --                    --
     Write down of product rights                            374,128                    --                    --

   Changes in non-cash working capital
     Accounts receivable                                      52,663                (2,895)               (9,269)
     Prepaid expenses                                         (1,467)                1,886                  (543)
     Accounts payable and accrued liabilities                 (6,791)              (16,971)              (16,847)
     Inventory purchases                                     (55,734)                  100                    --
----------------------------------------------------------------------------------------------------------------
                                                            (896,328)             (334,978)             (235,558)

Financing
     Issuance of capital stock                             1,041,008               406,749                80,377
     Issuance of redeemable preferred shares
       of subsidiary                                         309,677                    --                    --
----------------------------------------------------------------------------------------------------------------
                                                           1,350,685               406,749                80,377

Investing
     Acquisition of capital assets                           (54,183)                 (396)              (41,629)
     Acquisition of product rights and patents              (381,336)                   --                 3,887
     Acquisition of shares                                   374,952                    --
----------------------------------------------------------------------------------------------------------------
                                                             (60,567)                 (396)              (37,742)


Foreign currency translation adjustment                       24,161                   (70)                   --
----------------------------------------------------------------------------------------------------------------
Increase (decrease) in cash                                  417,951                71,305              (192,923)

Cash, beginning of period                                         --               346,646               548,197

----------------------------------------------------------------------------------------------------------------
Cash, end of year                                        $   417,951           $   417,951           $   355,274
----------------------------------------------------------------------------------------------------------------
</TABLE>


See accompanying notes to financial statements


                                       5
<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statement of Stockholders' Equity and Comprehensive Income
$ United States

For the nine months ended February 29, 2000 and 1999
<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------------------------------
                                                                              Deficit
                                    Capital Stock                         Accumulated     Accumulated
                               ------------------------     Additional     During the           Other          Total
                                 Number                        Paid in    Development   Comprehensive  Stockholders'
                               of Shares         Amount        Capital          Stage          Income         Equity
--------------------------------------------------------------------------------------------------------------------

<S>                            <C>          <C>            <C>            <C>             <C>            <C>
Common shares issued
  net of share issue costs     2,410,947    $     2,411    $   472,355    $        --     $        --    $   474,766

Common shares issued
  to subscribers for shares
  of subsidiary Company
  (note 2)                     3,072,300          3,072        601,928             --              --        605,000

Excess of consideration
  given over carrying amount
  of net assets of subsidiary
  acquired (note 2)                   --             --             --       (132,736)             --       (132,736)

Comprehensive income:
  Loss                                --             --             --       (293,239)             --       (293,239)
  Foreign currency translation        --             --             --             --           6,288          6,288
--------------------------------------------------------------------------------------------------------------------
Comprehensive income (loss)           --             --             --       (293,239)          6,288       (286,951)
--------------------------------------------------------------------------------------------------------------------
Balance, May 31, 1998
  (Unaudited)                  5,483,247          5,483      1,074,283       (425,975)          6,288        660,079

Common shares issued
  net of share issue costs        36,300             36         96,726             --              --         96,762

Share subscriptions received
  for 19,302 shares at $3.25
  per share                           --             19         62,712             --              --         62,731

Comprehensive income:
  Loss                                --             --             --       (726,055)             --       (726,055)
  Foreign currency translation        --             --             --             --          17,038         17,038
--------------------------------------------------------------------------------------------------------------------
Comprehensive income (loss)           --             --             --       (726,055)         17,038       (709,017)
--------------------------------------------------------------------------------------------------------------------
Balance, May 31, 1999          5,519,547          5,538      1,233,721     (1,152,030)         23,326        110,555

Common shares issued
  net of share issue costs        71,250             96        233,734             --              --        233,830

Common shares issued for
  conversion of share
  subscriptions                   19,302             --             --             --              --             --

Share subscriptions received
  for 53,206 shares at $3.25
  per share                           --             53        172,866             --              --        172,919

Comprehensive income:
  Loss                                --             --             --       (329,618)             --       (329,618)
  Foreign currency translation        --             --             --             --              70             70
--------------------------------------------------------------------------------------------------------------------
Comprehensive income (loss)           --             --             --       (329,618)             70       (329,548)
--------------------------------------------------------------------------------------------------------------------
Balance, February 29, 2000     5,610,099    $     5,687    $ 1,640,321    $(1,481,648)    $    23,396    $   187,756
--------------------------------------------------------------------------------------------------------------------
</TABLE>


                                       6
<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements
$ United States

--------------------------------------------------------------------------------

L.O.M.  Medical  International Inc. was incorporated on March 17, 1997 under the
General  Corporation Laws of Delaware.  It conducts  research and development on
new  products  in the  medical  field  and has filed a patent  application  on a
retractable syringe. Operations effectively commenced on June 1, 1997.

1.   Significant accounting policies:

     a)   Going concern

          These  financial  statements  have been  prepared on the going concern
          basis,  which assumes the  realization  of assets and  liquidation  of
          liabilities  in  the  normal  course  of  business.  As  shown  in the
          consolidated financial statements,  to date, the Company has generated
          no  revenues  and  has   accumulated  a  deficit  since  inception  of
          $1,481,648.  This factor,  among others raises substantial doubt about
          the Company's  ability to continue as a going  concern.  The Company's
          ability to continue as a going  concern is dependent on its ability to
          generate future profitable  operations and receive continued financial
          support from its stockholders and other investors.

          Management's  plans  with  respect  to  generating  future  profitable
          operations include future sales of the retractable  syringe as well as
          additional  funding from  stockholders in the form of additional share
          subscriptions.

     b)   Translation of financial statements

          The Company's subsidiary,  L.O.M. Laboratories Inc. operates in Canada
          and its operations are conducted in Canadian currency.

          The method of translation applied is as follows:

          i)   Assets and  liabilities are translated at the rate of exchange in
               effect at the balance sheet date, being US $1.00 per Cdn $1.44

          ii)  Revenues  and  expenses are  translated  at the exchange  rate in
               effect at the transaction date.

          iii) The net  adjustment  arising from the  translation is included in
               accumulated other comprehensive income.

     c)   Basis of presentation and consolidation

          The  consolidated  financial  statements  include the  accounts of the
          Company and its 96% owned subsidiary, L.O.M. Laboratories Inc.

     d)   Product rights and patent costs

          Product  rights and patent costs relate to amounts paid to acquire the
          rights  to  produce  and  distribute  products  as well  as the  costs
          associated with patent  applications.  These costs are being amortized
          on a straight-line basis over five years.


                                       7
<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements, page 3
$ United States

--------------------------------------------------------------------------------


1.   Significant accounting policies (continued):

     d)   Product rights and patent costs (continued)

          Management  periodically  reviews the  carrying  values of the product
          rights and patent costs and based upon several factors,  including the
          current assessment of the viability of the product, determines whether
          the carrying value exceeds the net realizable value for such costs. If
          it is  determined  that the carrying  value cannot be  supported,  the
          related  costs  are  changed   against   operations  in  the  year  of
          determination of the impairment in value.

     e)   Capital assets

          Capital  assets are recorded at cost.  Amortization  is provided using
          the following  methods and annual rates which are intended to amortize
          the cost of the assets over their estimated useful life:

--------------------------------------------------------------------------------
         Asset                                  Method                 Rate
--------------------------------------------------------------------------------

         Leasehold improvements          Straight-line                  20%
         Computer software               Straight-line                 100%
         Equipment                   Declining balance                  30%
         Furniture and fixtures      Declining balance                  20%
--------------------------------------------------------------------------------

     f)   Income taxes

          The  Company  accounts  for  income  taxes by the asset and  liability
          method. Under the asset and liability method,  deferred tax assets and
          liabilities   are   recognized   for  the  future   tax   consequences
          attributable to differences  between the financial  statement carrying
          amounts of existing assets and  liabilities  and their  respective tax
          bases and operating  loss and tax credit  carryforwards.  Deferred tax
          assets and  liabilities  are measured using enacted tax rates expected
          to apply to  taxable  income  in the  years in which  those  temporary
          differences  are expected to be  recovered  or settled.  The effect on
          deferred  tax  assets  and  liabilities  of a change  in tax  rates is
          recognized in income in the period that includes the enactment date.

     g)   Management estimates

          The  preparation of financial  statements in conformity with generally
          accepted  accounting  principles  in  the  United  States  of  America
          requires  management to make estimates and assumptions that affect the
          reported   amounts  of  assets  and  liabilities  and  disclosures  of
          contingent  assets  and  liabilities  at the  date  of  the  financial
          statements  and the reported  amounts of revenues and expenses  during
          the  reporting   period.   Actual  results  could  differ  from  those
          estimates.


                                       8
<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements, page 4
$ United States

--------------------------------------------------------------------------------

1.   Significant accounting policies (continued):

     h)   Financial instruments

          The  fair  values  of the  Company's  cash,  accounts  receivable  and
          accounts payable and accrued  liabilities  approximate  their carrying
          values  due  to  the  relatively  short  periods  to  maturity  of the
          instruments.  It is  not  possible  to  arrive  at a  fair  value  for
          redeemable preferred shares as a public market for this stock does not
          exist.  The maximum  credit risk exposure for all financial  assets is
          the carrying amount of those assets.

     i)   Loss per share

          Loss per share has been calculated  using the weighted  average number
          of common shares outstanding during the period.

     j)   Accounting standards change

          In June 1998, the Financial Accounting Standards Board issued SFAS no.
          133,  "Accounting for Derivative  Instruments and Hedging Activities."
          Adoption  of this  statement  is not  expected  to have a  significant
          impact on the Company's results of operations or financial position.

2.   Business combination:

     Effective June 1, 1997, the Company acquired 96% of the outstanding Class A
     common voting shares of L.O.M.  Laboratories  Inc. Prior to and immediately
     after the acquisition, L.O.M. Laboratories Inc. was controlled by a related
     party,   the  president  and   controlling   shareholder  of  the  Company.
     Accordingly,  this  transaction has been measured at the carrying amount of
     the assets and liabilities of L.O.M.  Laboratories Inc. with the difference
     between the carrying amount and the exchange  amount  reflected as a charge
     to equity. Details of the acquisition are as follows:

--------------------------------------------------------------------------------

     Net assets (liabilities) acquired at carrying amounts
       Cash                                                        $     375,000
       Non-cash current assets                                            82,000
       Product rights and patent costs                                    22,000
       Capital assets                                                     14,000
       Current liabilities                                              (26,224)
       Share subscriptions                                             (605,000)
       Minority interest                                                   5,536
--------------------------------------------------------------------------------
                                                                       (132,688)
       Excess of consideration given over carrying amount
         of net assets acquired                                         132,736
--------------------------------------------------------------------------------
     Consideration given:
       Cash                                                        $          48
--------------------------------------------------------------------------------


                                       9
<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements, page 5
$ United States

--------------------------------------------------------------------------------


3.   Product rights and patent costs:

--------------------------------------------------------------------------------
                                                        2000                1999
--------------------------------------------------------------------------------
     Product rights                                 $     --           $      68
     Patent costs                                     13,546              16,672
--------------------------------------------------------------------------------
                                                    $ 13,546           $  16,740
--------------------------------------------------------------------------------

     Product rights represent certain rights to manufacture and market a contact
     lens  inserter  and  storage  system  ("Lens-o-matic")   developed  by  the
     president of the Company.

     At the time of the  acquisition of the product rights from the president of
     the Company,  the value  attributed to the product  rights,  $380,885,  was
     agreed to by the Company's  Board of  Directors.  During the year ended May
     31, 1999, the investment was written down to a nominal  amount,  due to its
     speculative nature.

     Patent costs  relate to the costs  incurred  for patent  application  for a
     retractable syringe developed by the Company.

4.   Capital assets:
<TABLE>
<CAPTION>
----------------------------------------------------------------------------------------------------------
                                                                                     2000             1999
----------------------------------------------------------------------------------------------------------
                                                            Accumulated          Net book         Net book
                                               Cost        amortization             value            value
----------------------------------------------------------------------------------------------------------

----------------------------------------------------------------------------------------------------------
     <S>                                     <C>                 <C>               <C>           <C>
     Leasehold improvements                  27,919               9,772            18,147        $  22,335
     Computer software                          520                 488                32              130
     Equipment                               20,948              12,558             8,390           10,826
     Furniture and fixtures                  21,113               6,673            14,440           16,578

----------------------------------------------------------------------------------------------------------
                                          $  70,500          $  29,491          $  41,009        $  49,869
----------------------------------------------------------------------------------------------------------

<CAPTION>

5.   Redeemable preferred shares:

     The Company's  subsidiary has redeemable  preferred  shares  outstanding as
follows:

--------------------------------------------------------------------------------------------
                                                                   2000                 1999
--------------------------------------------------------------------------------------------
     <S>                                                         <C>                 <C>
     Issued:
     4,000 Class C preferred shares with a par value of $100
     Cdn redeemable at $110.16 Cdn per share at the option
     of the holder. Each share is entitled to a fixed
     non-cumulative dividend at the rate of 9% per annum
     payable at such times as determined by the Directors.       301,727             301,727
--------------------------------------------------------------------------------------------
</TABLE>


                                       10
<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements, page 6
$ United States

--------------------------------------------------------------------------------

6.   Capital stock:

     a)   Authorized:

          50,000,000 Common shares with a par value of $.001 each 5,000,000
          Preferred shares with a par value of $.001 each

     b)   Share subscriptions:

       Subsequent to February 29, 2000,  the Company issued 53,206 common shares
         at $3.25 per share for net  proceeds of $172,866,  which were  received
         prior to February 29, 2000.

     c)   Stock option plan:

          1,000,000 common shares of the Company are reserved for issuance upon
          exercise of stock options. As at May 31, 1999, no stock options have
          been granted.

7.   Related party transactions:

     During the period the Company entered into the following transactions with
     related parties:
<TABLE>
<CAPTION>
---------------------------------------------------------------------------------------------------------
                                                                                  2000               1999
---------------------------------------------------------------------------------------------------------

     <S>                                                                    <C>                <C>
     Legal and accounting fees paid to a director                          $    10,425        $     8,500
     Management fees paid to president                                          45,729             52,991
     Office and administration fees paid to president's spouse                  26,668             47,813
     Rent paid to a company controlled by the president                         14,779             14,779

---------------------------------------------------------------------------------------------------------
</TABLE>

     These  transactions are in the normal course of operations and are measured
     at the exchange  amount of  consideration  established and agreed to by the
     related parties.


8.   Income taxes:

     At May 31, 1999,  the Company had a net  operating  loss  carryforward  for
     United  States  income tax purposes of  approximately  $1,000,000.  The net
     operating  loss expire in increments  beginning in 2008. No amount has been
     reflected on the balance sheet for future income taxes as any future income
     tax asset has been fully offset by a valuation allowance.


                                       11
<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements, page 7
$ United States

--------------------------------------------------------------------------------

9.   Commitments:

     The Company is obligated to make future lease payments for its offices as
     follows:

         2000                                             $       9,900
         2001                                             $      19,453
         2002                                             $      19,453
         2003                                             $      19,453
         2004                                             $      19,453

10.  Subsequent Events:

     At the Feb 28, 2000 board meeting, the board of directors approved, subject
     to legal  review,  the issuance of one warrant for every two shares held on
     March  15,  2000.  The  entitlement  for  each  warrant  has not  yet  been
     determined.  The board also  approved an option plan for the board  members
     which would allow board  members to  purchase  5,000  shares  annually at a
     market based price once a year.

Item 2.  Management's Discussion and Analysis or Plan of Operation

Development of the Registrant.  L.O.M.  Medical  International  Inc., a Delaware
corporation ("Company"),  was incorporated in the State of Delaware on March 17,
1997.  The  executive  offices of  Registrant  are located at #580-885  Dunsmuir
Street,  Vancouver,  British Columbia,  Canada V6C 1N8.  Registrant's  telephone
number is 604.602.9400.

As a point of clarification,  as used in this Registration  Statement,  the word
"Dollars"  and the  symbol "$" means and  refers to the  currency  of the United
States  of  America,  unless  otherwise  stated.  As used  in this  Registration
Statement,  the term  "CDN$"  means and refers to the  currency  of  Canada,  in
Canadian dollars.

Registrant  was  originally  incorporated  for the  purpose of  researching  and
developing  health  care  products.  The  goal of  Registrant  is to  become  an
innovator and provider of a retractable syringe ("Syringe") and related products
and   technologies  to  the  health  care  market.   Registrant  also  hopes  to
successfully market and distribute its line of eye care products. Registrant has
successfully  patented  and licensed  products in  twenty-four  other  countries
including the United  States and Canada.  Registrant  envisions  that it will be
able to develop new and improved  products and provide the health care  industry
with better, safer products throughout the world.

The  Syringe.  Registrant  anticipates  that the Syringe  will  change  standard
disposal methods for used syringes.  In this regard,  Registrant has developed a
product  designed  to  function  as  a  standard  hypodermic  syringe  with  one
difference:  it is safer and less  perilous  to the  caregiver  or  health  care
worker.  Registrant  believes that the Syringe's unique design will allow health
care providers to avoid direct contact with used needles. The Syringe is covered
by United States Patent No. 5,868,713 dated February 9, 1999, and  international
patents have been filed in 24 different countries.

Once the needle is injected, the user simply has to press the plunger top gently
with his or her thumb to  automatically  retract  the needle into its own sealed
chamber. The needle is now hidden where it remains locked in place and cannot be
used again.  The Syringe does not require a health care worker to use both hands
to retract the needle after it has been used and withdrawn from the patient. The
Syringe  will  be  produced  in  standard  industry  sizes  from  1CC  to 20 CC,
inclusive.  Registrant  anticipates that the products and technologies developed
by Registrant  will be offered to  distributors  on a worldwide  basis,  with an
initial emphasis in Canada and the United States.


                                       12
<PAGE>


Registrant  anticipates  that it will be testing the Syringe in conjunction with
teaching  universities in Canada,  Britain, and other constituents of the United
Kingdom.  Testing of the  Syringe  has not yet begun.  We hope to begin  testing
after the first  prototype is completed in or around July,  2000. The Registrant
believes it has commitments  from teaching  hospitals that will test the Syringe
once it is available.

The Lens-O-Matic. Registrant has invented and developed an insertion and storage
device for contact lenses (the "Lens-O-Matic")  which is an ideal medical method
of handling and inserting contact lenses. Registrant has developed the following
components  and  solutions  that  will be used  together  with the  Lens-O-Matic
insertion and storage  system:  (1) a medical  inserter that will remove contact
lenses in a medical  emergency  situation for use by hospital  medical staff and
paramedics; (2) disposable and replacement inserter ends; (3) additional storage
cups and caps;  and (4) all soaking and  disinfecting  solutions  that are to be
used with the Lens-O-Matic inserter.

The Lens-O-Matic is designed so that the practitioner will no longer have direct
hand or  finger  contact  with  the  contact  lens  when  fitting  the  patient.
Registrant  believes that the design of the Lens-O-Matic will reduce the risk of
contamination  and infection to the patient.  Registrant  has developed a liquid
cleaner for the Lens-O-Matic that quickly cleans contact lenses.  Registrant has
obtained  Food and Drug  Administration  Approval  ("FDA") for the  Lens-O-Matic
product.  Registrant  has also  completed  market  testing and believes that the
Lens-O-Matic  was well received at the A.O.A.  convention  in Montreal,  Canada,
where approximately 30,000 units were distributed to opticians, optometrists and
pharmacies.  Registrant has also  completed the  formulation of its contact lens
solutions  and  copyrights   covering  these  products  have  been   registered.
Registrant  has also  completed  the design  and  labeling  of the  Lens-O-Matic
package. Registrant has begun to market its eye-care products.

The target markets for the distribution  for the  Lens-O-Matic  product include,
but are not  necessarily  limited  to,  (i)  hospitals  and  clinics,  including
Shippert  Medical  of  Englewood,  Colorado  ("Shippert"),  Cross  Mark  Sales &
Marketing of Plano, Texas; and (ii) optometrists and opticians including, Health
Care Insights of Edison, New Jersey.

The Syringe.  Registrant  anticipates that it will obtain the necessary  plastic
for the injection  molds used to manufacture  the Syringe from various  domestic
and international  suppliers.  Initially,  Tessey Plastics of Elbridge, New York
will be  manufacturing  the Syringe on a contract basis. The engineering for the
molds and production dyes are near completion. Registrant also contemplates that
it will be able to  readily  obtain the  necessary  packaging  for the  Syringe.
Registrant does not believe that its sales will be affected by seasonal factors.
Registrant  believes that prototypes of the Syringe will be ready for testing in
July, 2000. Registrant believes that it will complete testing in Canada and gain
the necessary  regulatory  approvals in or around  September,  2000.  Registrant
believes it will complete the necessary  United States testing as well as secure
the required United States regulatory approval in or around the end of November,
2000.

As previously  discussed,  Registrant hopes to eventually establish a production
facility  in Spokane,  Washington.  It is  anticipated  that the  facility  will
initially  produce  approximately  2,500,000 units of the Syringe per month with
the capacity to meet increased market demands.  Registrant believes that it will
deliver its products to the North  American  markets by courier.  All supply and
distribution agreements will be negotiated by Health Care Insights.

Once testing of the Syringe is completed, and assuming FDA approval is received,
Registrant hopes to manufacture, or cause to be manufactured, a specified number
of units of the Syringe, which will be provided, at no charge, to a target group
of  physicians  for  testing.  Registrant  plans to  provide  units  to  various
individuals who are to form part of the testing group. These individuals will be
asked to try the Syringe and report their findings. Registrant will then utilize
professionals such as doctors and related health care professionals who approve,
recommend and endorse Registrant's products,  including the Syringe. Thereafter,
Registrant  anticipates  that the Syringe  will be  supplied  to large  national
distributors within specific regions all over the world.  Registrant anticipates
that the distributors will thereafter market the Syringe to pharmacy and medical
supply  companies.   Registrant's   overall  operating  plan  is  to  act  as  a
manufacturer,  selling  directly  and only to  distributors  and retail  chains.
Registrant hopes that the product will gain acceptance in the medical  community
and that  Registrant's  skill in positioning and  merchandising the products and
technology of  Registrant  will enable it to acquire a  commercially  reasonable
portion of the market.

Lens-O-Matic.  Registrant  anticipates  that its eye care  products will be sold
both by  retail  stores  and as a kit  distributed  by the  medical  profession.
Registrant  expects that its eye care products will be sold through  pharmacies,
wholesale drug distributors and chain stores and that such products will be sold
to   Optometrists   and   Ophthalmologists   directly  by   Registrant's   sales
representatives.   Registrant   has  recently   secured  FDA  approval  for  the
manufacturing and distribution


                                       13
<PAGE>


of a first product run of its eye-care products.  We have developed our own dyes
and injection molds for our Lens-O-Matic and related products.  We have paid for
all of the dyes and molds and currently  own them.  The first product run of our
eye care  products  includes  the  utilization  of our  production  dyes at full
capacity, the production of a marketable product which exceeds FDA standards for
medical  devices.  We manufacture the necessary  components for the Lens-O-Matic
and related  products in  Saskatchewan,  Canada.  Registrant is negotiating with
Shippert Medical Technologies of Englewood,  Colorado  ("Shippert")  pursuant to
which Registrant anticipates that Shippert will distribute  Registrant's product
line in the United States. Registrant has entered into a contract with a medical
distribution  company in Turkey  whereby  Registrant  will  provide a minimum of
5,000 units of the Lens-O-Matic per month. If the contract is performed to term,
Registrant  believes the value to Registrant  will be  US$240,000.00.  The first
5,000 units are now in transit.

Registrant plans to focus its initial marketing efforts in Canada and the United
States.  Registrant hopes to eventually  expand its product  marketing and sales
into Europe, South America,  Central America,  Mexico and Asia. Registrant plans
to market its  products by  advertising  in catalogs  and medical  journals,  by
distributing  brochures (both written and video), by direct mail and by posters.
Follow-up  calls will be made to  promising  prospects.  This  approach  will be
Registrant's   primary  marketing  method.  It  is  expected  that  Registrant's
personnel  will attend  various trade shows and medical  conventions in order to
introduce the Syringe with the hope of gaining endorsements and approvals. There
can be no assurance  that  Registrant  would be able to  establish  successfully
other methods of marketing and sales of its products should it become  necessary
or desirable in the future. A significant  portion of Registrant's  sales may be
made through  independent  distributors over which Registrant has no control and
who also will represent products of other companies.  Registrant recognizes that
in order  to  increase  market  awareness  and the  marketing  potential  of its
products, it must hire adequate personnel and institute effective advertising in
the most cost effective way.

Registrant is not currently producing commercial  quantities of its products nor
is it currently supplying any services to any third parties. No assurance can be
given that  Registrant,  on a timely basis,  will be able to make the transition
from manufacturing  testing  quantities of the Syringe to commercial  production
quantities  successfully  or be  able to  arrange  for  contract  manufacturing.
Registrant has produced testing quantities  amounting to 33,000 units of its eye
care  products.  Registrant's  current  production  capacity  does allow for the
production of commercial  quantities of its eye care products,  with its present
dyes allowing for the production of 75,000 units per month.  Registrant believes
that this can be  increased  to  150,000  units by  running  additional  shifts.
Registrant  has a second  set of dyes  designed  that will  have a 300,000  unit
capacity  which would allow the  production  for a total of 450,000 units of its
eye care products per month.  Registrant does anticipate that it will be able to
manufacture its products for initial commercialization.

Registrant  anticipates  that it  will  contract  out the  first  two  years  of
production  of the  Syringe.  At  the  end of the  second  year  of  production,
Registrant  anticipates it will engage in significant  discussions regarding the
potential  for the  construction  of its  own  production  facility.  Registrant
recognizes  that  the  construction  of its  own  production  facility  will  be
contingent upon its having reached its sales and profit projections.  Registrant
anticipates  that it will  present this issue for vote by its Board of Directors
and shareholders. In this regard, Registrant anticipates that it will locate its
production facilities in North America,  specifically,  the state of Washington,
due to its  strategic  location  for  penetration  into the  United  States  and
Canadian markets.

As previously  discussed,  Registrant's eye care products are currently produced
in Canada.  Registrant  owns all of the necessary  injection  molds.  Registrant
contracts  out for the  production  of  components  needed for the  assembly and
packaging of its eye care products.  The actual  assembly and packaging are done
by Registrant's own work force.  All other products of Registrant,  those either
currently in production or the subject of future  production will be produced on
a contract  basis through plants that are FDA approved for production of medical
products.

Registrant is currently  negotiating with the Irish Development Board in Ireland
("Development Board").  Representatives from the Development Board have met with
Registrant's  Board of  Directors on 3 different  occasions  and have offered to
assist Registrant in establishing a production  facility in Ireland.  Registrant
has already sent  representatives  to Ireland to discuss the  production  of the
Syringe  as  well  as  strategic   alliances  for  market  distribution  of  all
Registrant's products. Registrant's plans to construct a production facility are
merely  preliminary.  As such,  Registrant  has not reached an estimation of the
capital resources necessary to fund such a project nor has Registrant determined
how long such a project would take to complete.  Registrant  anticipates that at
the end of the  projected  two-year  period,  Registrant  will have a sufficient
revenue stream to finance, at least partially,  the construction of the proposed
production  facilities.  However, there can be no assurance that Registrant will
have the  necessary  funds at the end of the two-year  period to  construct  its


                                       14
<PAGE>


proposed production facilities.  Should Registrant not have the necessary funds,
Registrant  anticipates it will continue to cause its products to be produced on
a contract basis.

Currently,  Registrant does have the necessary production  facilities to produce
its line of eye care products on a commercial basis. Registrant has FDA approval
to  market  its  line of eye  care  products  in the  United  States.  Also,  as
previously  discussed,  Registrant has the necessary Canadian approval to market
its eye-care products in Canada. Shippert Medical will be marketing Registrant's
eye care  products  in the United  States as well as in Canada.  Registrant  has
entered into a marketing and distribution  contract with Shippert  Medical.  The
contract has an initial two-year term with a two-year renewal option.

Business of Registrant's Subsidiary. On or about June 1, 1997, Registrant agreed
to purchase  4,800 of the 5,000 total  issued and  outstanding  shares of L.O.M.
Laboratories Inc.'s ("L.O.M.  Laboratories") Class "A" common shares. Registrant
agreed to pay  US$1.00  per share.  This  represents  a 96%  interest  in L.O.M.
Laboratories.  L.O.M.  Laboratories owned the rights to the Lens-O-Matic  system
until January 1, 1998,  when  Registrant  purchased those rights for US$380,885.
The  primary  business  purpose of the  subsidiary  is to develop and market new
products through  Registrant.  L.O.M.  Laboratories has developed a line of skin
care products.  We hope that the line of skin care products will be produced and
marketed in or around August,  2000.  Registrant has applied for patents for the
line of skin care products in both the United States and Canada.

Liquidity. The Registrant had cash resources of US$417,951 at February 29, 2000.
At February 28, 1999, the Registrant  had cash  resources of  US$346,646.00.  At
February 29, 2000, the Registrant had total current assets of US$448,755.00  and
total current  liabilities of US$19,363.00.  At February 29, 2000, total current
assets  exceeded  total current  liabilities by  US$429,412.00.  At February 28,
1999,  Registrant  had total current assets of  US$376,541.00  and total current
liabilities of US$36,404.00. At February 28, 1999, total current assets exceeded
total current liabilities by US$340,137.00.  The cash and equivalents constitute
the  Registrant's  present  internal  sources of liquidity.  Because neither the
Registrant  nor its subsidiary are  generating  any  significant  revenues,  the
Registrant's only external source of liquidity is the sale of its capital stock.

Results of  Operations.  The  Registrant  has not yet realized  any  significant
revenue  from  operations.  The net loss from  operations  from  March 17,  1997
(inception)  to February 29,  2000,  was  US$1,348,912.00.  The net loss for the
9-month period ended February 29, 2000 was  US$329,618.00.  The net loss for the
9-month period ended February 28, 1999, was US$222,145.00.  The net loss for the
3-month period ended February 29, 2000, was US$131,789.00.  The net loss for the
same period in 1999 was  US$74,043.00.  Such losses were primarily the result of
selling,  general  and  administrative  expenses,   management  fees,  rent  and
consulting fees.

The Registrant may require additional cash to implement its business strategies,
including cash for (i) payment of increased  operating expenses and (ii) further
implementation of those business strategies. No assurance can be given, however,
that the Registrant  will have access to the capital  markets in the future,  or
that  financing  will be  available  on  acceptable  terms to  satisfy  the cash
requirements  of the  Registrant  to  implement  its  business  strategies.  The
inability of the Registrant to access the capital  markets or obtain  acceptable
financing could have a material  adverse effect on the results of operations and
financial conditions of the Registrant.

The  Registrant's  forecast of the period of time  through  which its  financial
resources  will be  adequate  to support  its  operations  is a  forward-looking
statement that involves risks and  uncertainties,  and actual results could vary
as a result of a number of factors.

The Registrant  anticipates that it will need to raise additional capital within
the next 12 months in order to  develop,  promote,  produce and  distribute  its
proposed  products.  Such  additional  capital may be raised through  additional
public or private financings,  as well as borrowings and other resources. To the
extent  that  additional  capital  is  raised  through  the  sale of  equity  or
equity-related  securities,  the  issuance of such  securities  could  result in
dilution  of the  Registrant's  stockholders.  There  can be no  assurance  that
additional  funding will be available on favorable terms, if at all. If adequate
funds  are not  available  within  the next 12  months,  the  Registrant  may be
required to curtail its  operations  significantly  or to obtain  funds  through
entering  into  arrangements  with  collaborative  partners  or others  that may
require the Registrant to relinquish  rights to certain of its products that the
Registrant would not otherwise relinquish.


                                       15
<PAGE>


Registrant,  being  a  developmental  stage  enterprise,  is  currently  putting
technology in place which will, if successful, mitigate the net loss experienced
by Registrant.  Registrant is reviewing its options to raise substantial  equity
capital.  Management has proceeded as planned in the ongoing  development of the
Syringe and the Lens-O-Matic.  In order to meet its requisite budget, management
has held and continues to conduct  negotiations  with investors.  Registrant has
also  conducted  extensive  negotiations  with various  medical  companies in an
attempt to establish beneficial strategic alliances. Registrant hopes that these
negotiations  will result in significant  investment  income for Registrant.  To
achieve and maintain the  competitiveness  of its products and to conduct costly
and time-consuming research and development, Registrant may be required to raise
substantial  funds in addition to the funds already  raised through the issuance
of  Registrant's  shares.  Registrant  will continue to develop its products for
commercial sale.  Registrant's forecast for the period of time through which its
financial   resources   will  be  adequate  to  support  its   operations  is  a
forward-looking  statement  that involves  risks and  uncertainties,  and actual
results  could fail as a result of a number of factors.  Registrant  anticipates
that it will need to raise  additional  capital  in order to  develop,  promote,
produce and  distribute  its  products.  Such  additional  capital may be raised
through additional public or private financings, as well as borrowings and other
resources.

There can be no  assurance  that  additional  funding  will be  available  under
favorable terms, if at all. If adequate funds are not available,  Registrant may
be required  to curtail  operations  significantly  or to obtain  funds  through
entering  into  arrangements  with  collaborative  partners  or others  that may
require  Registrant to  relinquish  rights to certain  products that  Registrant
would not otherwise relinquish.  However,  Registrant believes that it is poised
to maintain its  long-term  liquidity.  Registrant  believes that within a short
period of time,  it can begin  marketing  commercial  quantities of its eye care
products.  Coupled  with the  further  issuance of common  stock of  Registrant,
Registrant believes it can significantly improve its long-term liquidity.

The Registrant does not anticipate any material  expenditures within the next 12
months.  The  Registrant  does  not  anticipate  any  significant  research  and
development within the next 12 months,  nor does the Registrant  anticipate that
it will lease or purchase any significant  equipment  within the next 12 months.
The  Registrant  does not  anticipate a significant  change in the number of its
employees within the next 12 months.

Item 3.  Defaults Upon Senior Securities

None

Item 4.  Submission of Matters to Vote of Security Holders

None

Item 5.  Other Information

None

Item 6.  Exhibits and Reports on Form 8-K

None


                                       16
<PAGE>


                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

Dated:   April __, 2000            L.O.M. Medical International, Inc.


                                          By:   /s/ John Klippenstein
                                                ------------------------
                                                John Klippenstein
                                          Its:  President


                                       17